These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35536994)

  • 1. Use of Cabozantinib to Treat MET -amplified Pediatric Colorectal Cancer.
    Fukui S; Umeda K; Kubota H; Iwai A; Akazawa R; Isobe K; Tanaka K; Kouzuki K; Kawabata N; Saida S; Kato I; Hiramatsu H; Itatani Y; Funakoshi T; Adachi S; Takita J
    J Pediatr Hematol Oncol; 2023 Apr; 45(3):e423-e426. PubMed ID: 35536994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers.
    Jia J; Howard L; Liu Y; Starr MD; Brady JC; Niedzwiecki D; Strickler JH; Nixon AB
    Cancer Chemother Pharmacol; 2022 Mar; 89(3):413-422. PubMed ID: 35171350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model.
    Sun Y; Sun L; An Y; Shen X
    Med Sci Monit; 2015 Aug; 21():2316-21. PubMed ID: 26255947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
    Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH
    J Clin Oncol; 2017 Oct; 35(29):3315-3321. PubMed ID: 28817373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma.
    Wedekind MF; Ranalli M; Shah N
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28417541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
    Goyal L; Zheng H; Yurgelun MB; Abrams TA; Allen JN; Cleary JM; Knowles M; Regan E; Reardon A; Khachatryan A; Jain RK; Nardi V; Borger DR; Duda DG; Zhu AX
    Cancer; 2017 Jun; 123(11):1979-1988. PubMed ID: 28192597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
    Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
    J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
    Song EK; Tai WM; Messersmith WA; Bagby S; Purkey A; Quackenbush KS; Pitts TM; Wang G; Blatchford P; Yahn R; Kaplan J; Tan AC; Atreya CE; Eckhardt G; Kelley RK; Venook A; Kwak EL; Ryan D; Arcaroli JJ
    Int J Cancer; 2015 Apr; 136(8):1967-75. PubMed ID: 25242168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.
    Shang R; Song X; Wang P; Zhou Y; Lu X; Wang J; Xu M; Chen X; Utpatel K; Che L; Liang B; Cigliano A; Evert M; Calvisi DF; Chen X
    Gut; 2021 Sep; 70(9):1746-1757. PubMed ID: 33144318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
    Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
    [No Abstract]   [Full Text] [Related]  

  • 11. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
    Abdelaziz A; Vaishampayan U
    Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.
    Grüllich C
    Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to cabozantinib in renal cell carcinoma with cardiac metastases.
    Stellato M; Cursano MC; Citarella F; Pantano F; Russano M; Dell' Aquila E; Vincenzi B; Tonini G; Santini D
    Anticancer Drugs; 2020 Mar; 31(3):314-318. PubMed ID: 31929349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.
    Strickler JH; Rushing CN; Uronis HE; Morse MA; Niedzwiecki D; Blobe GC; Moyer AN; Bolch E; Webb R; Haley S; Hatch AJ; Altomare IP; Sherrill GB; Chang DZ; Wells JL; Hsu SD; Jia J; Zafar SY; Nixon AB; Hurwitz HI
    Oncologist; 2021 Jun; 26(6):465-e917. PubMed ID: 33469991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RET fusion in advanced non-small-cell lung cancer and response to cabozantinib: A case report.
    Wang Y; Xu Y; Wang X; Sun C; Guo Y; Shao G; Yang Z; Qiu S; Ma K
    Medicine (Baltimore); 2019 Jan; 98(3):e14120. PubMed ID: 30653139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.
    Yang S; Zhang X; Qu H; Qu B; Yin X; Zhao H
    Cancer Gene Ther; 2020 May; 27(5):368-377. PubMed ID: 31182761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.
    Zhao H; Nolley R; Chan AMW; Rankin EB; Peehl DM
    Cancer Biol Ther; 2017 Nov; 18(11):863-871. PubMed ID: 27715452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib in Patients with Advanced Merkel Cell Carcinoma.
    Rabinowits G; Lezcano C; Catalano PJ; McHugh P; Becker H; Reilly MM; Huang J; Tyagi A; Thakuria M; Bresler SC; Sholl LM; Shapiro GI; Haddad R; DeCaprio JA
    Oncologist; 2018 Jul; 23(7):814-821. PubMed ID: 29445030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activating mutation in MET oncogene in familial colorectal cancer.
    Neklason DW; Done MW; Sargent NR; Schwartz AG; Anton-Culver H; Griffin CA; Ahnen DJ; Schildkraut JM; Tomlinson GE; Strong LC; Miller AR; Stopfer JE; Burt RW
    BMC Cancer; 2011 Oct; 11():424. PubMed ID: 21970370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases.
    Klempner SJ; Borghei A; Hakimian B; Ali SM; Ou SI
    J Thorac Oncol; 2017 Jan; 12(1):152-156. PubMed ID: 27693535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.